The AACE update to its 2026 algorithm for the management of type 2 diabetes includes a new section on diabetes classification.
Tandem Diabetes Care has secured a new FDA clearance for its insulin dose-calculating algorithm, opening up its use to adults with Type 2 diabetes. The Control-IQ+ program—now with the added ...
The company aims to start a pivotal trial this year, file for 510(k) clearance in 2027 and launch the device in 2028.
The US Food and Drug Administration (FDA) has expanded the indication for Tandem Diabetes Care’s Control-IQ+ Technology to include people with type 2 diabetes (T2D). The next-generation Control-IQ+ ...
Obesity and type 2 diabetes are deeply interconnected. Yet, many diabetes prevention programs fail to adequately treat ...
Insulet (Nasdaq:PODD) shared new clinical evidence for its first fully closed-loop automated insulin delivery system for type 2 diabetes.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results